ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,067.00
-1.24%
S&P ASX All Technology
3,766.30
-0.74%
Brent Oil
72.72
0.00%
US Dollar vs AUD
1.59949
0.00%
Bitcoin
97,743.97
-0.02%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ocean Biomedical Inc (OCEA)

  7. Ocean Biomedical Inc (OCEA) News

OCEA

Ocean Biomedical (OCEA)

Ocean Biomedical Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OCEA
DateTimeSourceHeadlineSymbolCompany
23/11/202408:45GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
23/10/202407:45GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination LetterNASDAQ:OCEAOcean Biomedical Inc
01/10/202422:01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling ResponsesNASDAQ:OCEAOcean Biomedical Inc
27/08/202422:01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention PlatformsNASDAQ:OCEAOcean Biomedical Inc
24/08/202406:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
24/08/202406:30GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
24/07/202407:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
05/06/202421:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024NASDAQ:OCEAOcean Biomedical Inc
30/05/202421:44GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
16/05/202422:01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe DiseaseNASDAQ:OCEAOcean Biomedical Inc
25/04/202406:51GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-KNASDAQ:OCEAOcean Biomedical Inc
28/03/202423:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASLNASDAQ:OCEAOcean Biomedical Inc
09/03/202409:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
05/03/202409:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
01/03/202400:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver MeetingNASDAQ:OCEAOcean Biomedical Inc
14/02/202410:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCEAOcean Biomedical Inc
20/01/202409:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
18/01/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
06/12/202300:15GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 AntibodyNASDAQ:OCEAOcean Biomedical Inc
30/11/202309:41GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
15/11/202322:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
15/11/202322:20Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:OCEAOcean Biomedical Inc
15/11/202300:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
26/10/202320:30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
26/10/202320:30PR Newswire (US)Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
24/10/202321:30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan KurtisNASDAQ:OCEAOcean Biomedical Inc
17/10/202323:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
13/10/202308:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
12/10/202323:01PR Newswire (US)Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwideNASDAQ:OCEAOcean Biomedical Inc
12/10/202323:01GlobeNewswire Inc.Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients WorldwideNASDAQ:OCEAOcean Biomedical Inc
 Showing the most relevant articles for your search:NASDAQ:OCEA

Your Recent History

NYSE
VZ
Verizon Communications
COIN
SOLUSD
Solana
NASDAQ
QQQ
Invesco QQQ Trust Series 1
COIN
BTCUSD
Bitcoin
NYSE
MRK
Merck
ASX
WES
Wesfarmers
ASX
XMM
S&P ASX 300 Metals and M...
COIN
XRPUSD
Ripple
NASDAQ
AAPL
Apple
ASX
FMG
Fortescue
NYSE
JPM
JP Morgan Chase
COIN
AVAXUSD
Avalanche
ASX
CSL
CSL
NYSE
KO
Coca Cola
COIN
DOGEUSD
Dogecoin
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads